Effective December 21, 2015, we will be changing our name from Isis Pharmaceuticals to Ionis Pharmaceuticals. We made the decision to change our name because, when people hear our name, we want them to associate our name with the life-saving medicines we are developing and bringing to market. We have chosen the name “Ionis” (pronounced “eye-OH-nis”) as an original name to represent our innovative culture and heritage as both the pioneer and the leader in the RNA-targeted therapeutic space for the past 26 years. In conjunction with the corporate name change, we will also be changing our website address from www.isispharm.com to www.ionispharma.com. In addition, we will have a new email domain: @ionisph.com. However, visitors to our old website will be redirected to our new site and email sent to our old email addresses will still be delivered correctly. Our company address and phone numbers will not change. Beyond these superficial changes, the company will continue to operate as before. Our focus continues to be on bringing our late-stage Phase 3 drugs: nusinersen, volanesorsen and IONIS-TTRRx to the market and advancing our pipeline of high value drugs that have the potential to be first-in-class or best-in-class drugs to treat patients with life-threatening or serious diseases. As we move forward as Ionis Pharmaceuticals, we look forward to updating you on all of our exciting progress in the coming months and years. For questions concerning the name change, please contact me at ■■■■■■■■■■■■■■■■■■■.
Kristina Kristina Bowyer | Director, Patient Advocacy
Ionis Pharmaceuticals, Inc. | 2855 Gazelle Court | Carlsbad, CA 92010
Direct Dial: 760.603.2490 | Facsimile: 760.918.3595